is glp 1 gip tirzepatide Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Frontiers | Clinical perspectives on

A Rotterdam study has shown that the risk of AD in patients with T2MD is increased by 2-fold (42)

Source: UVA A new study from the University of Virginia reveals that a widely used class of weight-loss drugs does more than suppress appetiteit directly alters brain circuits that control motivation and reward

Rushing it produces more side effects without meaningfully accelerating results

TRIUMPH-4 (Phase 3, 68 weeks) 12mg dose: 28.7% weight loss (~71 lbs / 32 kg average) 9mg dose: 26.4% weight loss (~64 lbs / 29 kg average) Patients also saw 76% reduction in knee osteoarthritis pain Blood pressure reduced by 14 mmHg on average Source: ClinicalTrials.gov (TRIUMPH-4, NCT05931367) The TRIUMPH Phase 3 program includes 4 trials studying retatrutide for obesity, type 2 diabetes, and cardiovascular outcomes

Researchers measured, as primary outcomes, psychiatric hospitalisation, sick leave from work for more than 14 days for psychiatric reasons, hospitalisation due to self-harm, or taking ones own life